<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879942</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PLA-2016-31</org_study_id>
    <nct_id>NCT02879942</nct_id>
  </id_info>
  <brief_title>First Trimester Placental Assessment in the Screening of Preeclampsia and Intrauterine Growth Restriction</brief_title>
  <official_title>First-trimester Study of the Morphometric Characteristics of the Placenta to Assess the Risk of Preeclampsia and Intrauterine Growth Restriction in Singleton Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Clinical Research Network - CAIBER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <brief_summary>
    <textblock>
      Preeclampsia (PE) and intrauterine growth restriction (IUGR) are clinical manifestations of
      placental insufficiency. These complications affect 5-15% of pregnancies, and are responsible
      for up to 20% of preterm births. Women who develop PE during pregnancy also have an increased
      risk for cardiovascular events, both at short and long term. This justifies the need to
      improve diagnostic tools to identify patients at risk for these complications. PE and IUGR
      are multifactorial entities. Screening algorithms should thus include several parameters to
      achieve high detection rates. Research has mainly focused in the analysis of biophysical and
      biochemical parameters, and the study of the placenta itself has not been included in current
      diagnostic strategies. Investigators hypothesize that detection rates of preeclampsia and
      intrauterine growth restriction could be improved by the study of placental characteristics
      in the first trimester of pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of preeclampsia</measure>
    <time_frame>Up to birth</time_frame>
    <description>Pre-eclampsia is diagnosed after 20 week of gestation with systolic blood pressure equal to or greater than 140 mmHg, diastolic blood pressure equal to or greater than 90 mmHg and proteinuria greater than or equal 0.3 g/d by 24 hour urine collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of intrauterine growth restriction</measure>
    <time_frame>At birth</time_frame>
    <description>Intrauterine growth restriction is defined as birthweight below 10th centile according to local standards</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Case cohort</arm_group_label>
    <description>Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <description>Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultrasound study of the placenta</intervention_name>
    <description>The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.</description>
    <arm_group_label>Case cohort</arm_group_label>
    <arm_group_label>Control cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test</intervention_name>
    <arm_group_label>Case cohort</arm_group_label>
    <arm_group_label>Control cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples from the first blood test performed during pregnancy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with singleton pregnancies and ultrasonographic evaluation between 11+0 and 13+6
        weeks of gestation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnancies with fetuses with CRL between 45 and 80mm

          -  absence of chromosomal abnormalities

          -  absence of congenital anomalies

          -  absence of congenital infections

        Exclusion Criteria:

          -  patient not accepting to participate in the study

          -  multiple pregnancies

          -  pregnancies without ultrasonographic confirmation of gestational age
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Trilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Trilla, MD</last_name>
    <phone>+34935537041</phone>
    <email>trilla.cristina@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Trilla, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Placental volume</keyword>
  <keyword>First-trimester screening</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Intrauterine growth restriction</keyword>
  <keyword>Biochemical markers</keyword>
  <keyword>Uterine artery doppler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
    <mesh_term>Angiogenesis Inducing Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

